This study compared the abilities of ciprofloxacin and cefixime to kill intracellular Neisseria gonorrhoeae in a human fallopian tube organ culture assay. When invasion was inhibited by cytochalasin D, 0.996% of the tissue-associated gonococci survived ciprofloxacin exposure compared to 1.70% of gonococci exposed to cefixime (95% confidence interval for the ratio of the means, 0.267 to 1.30), indicating that the two antibiotics did not significantly differ in the ability to kill extracellular attached organisms. In the absence of cytochalasin D, 1.63% survived ciprofloxacin exposure while 9.76% survived cefixime treatment (95% confidence interval for the ratio of the means, 0.067 to 0.418). These results suggest that ciprofloxacin penetrated epithelial cells and killed intracellular gonococci better than did cefixime. Thus, at concentrations achievable in serum, ciprofloxacin was more effective in total gonococcal killing than cefixime in this human fallopian tube organ culture model.
An estimated 400,000 new cases of gonorrhea occurred in 1995 in the United States (8) . Although overall rates have been declining in the United States, a recent upsurge of gonorrhea in adolescents has been noted (7, 8) . Uncomplicated infections may involve the urethra or female cervix. Complicated infection may affect the upper genital tract, e.g., the epididymis or fallopian tubes. A common complication of gonococcal pelvic inflammatory disease is fallopian tube blockage, an effect that makes gonococcal infection a leading cause of infertility in women worldwide (27) . Approved single-dose antibiotic regimens for uncomplicated gonorrhea include intramuscular ceftriaxone or oral cefixime, ofloxacin, or ciprofloxacin (5). With multiple regimens from which to choose, more information about potential differences in killing efficacy among various drug classes would be beneficial.
Research studies on the pathogenesis of Neisseria gonorrhoeae have been hindered by the lack of an inexpensive animal model for the disease. This has led researchers to utilize cell line cultures and organ culture models. McGee et al. used a fallopian tube organ culture (FTOC) model to study gonococcal invasion. Four steps in the invasion process were outlined: attachment with tight adherence to nonciliated columnar epithelial cells, endocytosis into the epithelium, transcytosis through the cells, and finally, exocytosis of the organisms into subepithelial spaces (26) . This finding in the organ culture system corroborated histological observations of intracellular gonococci in fallopian tube, cervix, and urethral epithelium samples taken from patients (1, 11, 26, 38) . Since antimicrobial agents differ in the ability to penetrate cells, one might expect poorly penetrating antibiotics such as gentamicin (2, 9, 33, 34, 37) and the ␤-lactams (2, 26, 32) to be less effective in killing intraepithelial gonococci than the fluoroquinolones, which achieve high intracellular levels (2, 19, 24, 29) .
A gentamicin assay using cell line cultures has been used to distinguish intracellular from extracellular neisseriae (9, 33, 34, 37) . These experiments used cytochalasin D to inhibit gonococcal invasion by interfering with the cytoskeletal matrix of host epithelial cells. Simon and Rest showed that cytochalasin D inhibits invasion of ME-180 human cervical epithelial cells by Escherichia coli expressing gonococcal Opa proteins in a dose-dependent manner (34) . Gentamicin was used at concentrations much higher than those achievable in serum to kill external bacteria. Since gentamicin penetrates epithelial cells poorly, intracellular organisms were spared. This suggests that bactericidal concentrations in serum may not predict efficacy against facultative intracellular gonococci. If antibiotics used to treat gonococcal infections differ in the ability to kill intracellular gonococci, antibiotic choice might have significant clinical implications when MICs rise. In this study, the relative intracellular killing of ciprofloxacin versus cefixime was tested in the FTOC model of gonococcal infection. As an initial strategy, the feasibility of the approach was established by applying the gentamicin-cytochalasin D invasion assay to the FTOC model for documentation of microfilament-dependent gonococcal invasion of the fallopian tube epithelium. Gentamicin was replaced by ciprofloxacin or cefixime in subsequent experiments to determine if differences in their abilities to kill intracellular gonococci exist. In addition to the clinical implication of such differences, poor intracellular killing by one of the antibiotics might be harnessed to study the pathogenesis of gonococcal invasion in future experiments. Thus, a secondary goal of this study was to establish an invasion assay for the FTOC model based on differential killing of extracellular versus intracellular gonococci by antibiotics.
MATERIALS AND METHODS
Bacteria and susceptibility tests. N. gonorrhoeae 2686 was used in this study (22) . A piliated colony was selected based on morphology (15, 16, 23) , passaged on GC agar (Difco Laboratories, Detroit, Mich.) supplemented with 2% (vol/vol) IsoVitaleX (BBL Microbiology Systems, Cockeysville, Md.) (GCIso agar) at 37°C (5% CO 2 ), and stored at Ϫ70°C in fresh sheep erythrocytes. Piliation was verified by negative staining and use of a Philips CM10 transmission electron microscope. MIC testing was done with this isolate to assess susceptibility to gentamicin (Sigma Chemical Co., St. Louis, Mo.), ciprofloxacin (Bayer Corporation, West Haven, Conn.), and cefixime (Lederle Laboratories, Pearl River, N.Y.). The National Committee for Clinical Laboratory Standards guidelines were followed for a twofold agar dilution method using GC agar supplemented with 1% IsoVitaleX. N. gonorrhoeae 49226 (American Type Culture Collection, Rockville, Md.) was used as the control strain for MIC determinations (28) .
Media. Organ cultures were maintained in 0.05 M N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES)-buffered Eagle's minimal essential medium (MEM; Gibco BRL, Grand Island, N.Y.), pH 7.45, containing Earle's salts and L-glutamine (HEPES-MEM) (25) . During preparation of fallopian tubes and for 24 h thereafter, this medium was supplemented with vancomycin and colistin (each at 5 g/ml) to prevent contamination.
Human fallopian tube organ culture. Human fallopian tubes were removed from premenopausal women undergoing elective hysterectomy-salpingo-oophorectomy. Procurement of fallopian tube tissue from pathological specimens was done in accordance with institutional policies at participating hospitals. Procedures for the preparation, maintenance, and processing of FTOCs have been described previously (13, 25) . Following overnight incubation at 37°C (5% CO 2 ), the culture plates, each containing three round 2.5-mm-diameter tissue pieces, were washed twice at a 30-min interval with 1.50 ml of fresh HEPES-MEM. The plates were washed a third time with 1.35 ml of either HEPES-MEM or HEPES-MEM with 13.33-g/ml cytochalasin D (after inoculation, the final concentration was 12.00 g/ml). N. gonorrhoeae 2686 was harvested from GCIso agar after 18 to 20 h of growth and suspended in fresh HEPES-MEM. A 0.150-ml inoculum was added to organ cultures, resulting in a final concentration of 2 ϫ 10 5 CFU/ml (25) . Plates were incubated at 37°C (5% CO 2 ) for an additional 44 h.
Invasion assay. After 44 h of incubation, nonadherent bacteria were washed from the culture plates and tissue with either fresh HEPES-MEM or HEPES-MEM supplemented with 12.00-g/ml cytochalasin D. Half of the plates from each group were treated with gentamicin at 100 g/ml and incubated for an additional 3 h. Plates were washed three times with fresh HEPES-MEM at 30-min intervals and, after the last wash, homogenized for 60 s in 0.50 ml of HEPES-MEM by using a Tekmar Tissumizer (Tekmar Company, Cincinnati, Ohio) at 60% power (13,500 rpm). This power setting did not affect the viability of gonococci (data not shown). Viable bacteria in these samples were quantified by 10-fold plate dilution immediately after homogenization. Antifoam A at 2.5% (vol/vol) (Sigma Chemical Co.) was added to the remaining homogenate to remove bubbles. The protein concentrations in these samples were measured by using a Bradford protein assay (Bio-Rad Laboratories, Hercules, Calif.). Final results were expressed as CFU per milligram of protein.
After each homogenization, the Tissumizer probe was cleaned with 70% ethanol and rinsed with sterile phosphate-buffered saline (pH 7.4). This technique was shown to be effective in killing residual bacteria. The phosphatebuffered saline wash also was tested to verify that any residual ethanol was too dilute to affect the viability of organisms recovered from subsequent homogenization steps (data not shown).
Ciprofloxacin-versus-cefixime assay. To assess the differential intracellular antimicrobial efficacies of cefixime and ciprofloxacin, the experiment described above was duplicated during the initial 44-h infection period. In contrast, during the treatment of organ culture plates with antibiotic, HEPES-MEM was supplemented with 2.3-g/ml ciprofloxacin or 4.0-g/ml cefixime instead of gentamicin. Each of these drug concentrations reflects the midpoint in the range of levels achievable in serum following administration of a 500-mg oral dose of ciprofloxacin or a 400-mg oral dose of cefixime (31) . These are similar to isolated levels reported by a number of investigators (20, 21, 39) . Control assays were performed without antibiotics. All experiments were performed three times to show reproducibility of results.
Statistical analysis. The two-sample t test for confidence interval analysis (CIA) was used to assess statistical significance for each group of experiments. The data were normalized by logarithmic transformation. The differences between samples treated with and without cytochalasin D with each antibiotic were analyzed by 95% CIA by using the British Medical Journal's CIA software (12) . Confidence intervals for the means were reported by back transforming the confidence intervals for the log-transformed data.
Transmission electron microscopy. Additional experiments were conducted to verify gonococcal invasion within the FTOC model. Tissue punch biopsy samples were cut in half, fixed in Karnovsky's fixative, and secondarily fixed with 1% (vol/vol) OsO 4 . Specimens were dried in successive changes of ethanol, embedded in epoxy resin, sectioned with a diamond knife, and stained with uranyl acetate and lead citrate (4) . Ultrathin sections were examined with a Philips CM10 transmission electron microscope.
RESULTS
Bacteria and susceptibility tests. The agar dilution MICs of gentamicin, ciprofloxacin, and cefixime for N. gonorrhoeae 2686 were 8, 0.002, and 0.002 g/ml, respectively. These MICs fall within the range of MICs for 50% of the isolates taken from patients diagnosed with pelvic inflammatory disease caused by gonococci (30) . Thus, our test organism represents an average clinical isolate.
Invasion assays. Transmission electron microscopy verified invasion of epithelial cells at several time points following infection (data not shown). At 44 h postinfection, epithelial cells contained large numbers of intracellular gonococci. Thus, this time point was chosen to study differential intracellular antimicrobial efficacy.
Cytochalasin D was used at 12.00 g/ml to inhibit intracellular invasion by gonococci in half of the tissue samples tested. Cytochalasin D at this concentration did not significantly alter the growth or viability of gonococci (data not shown). Results of the invasion assay are shown in Table 1 . Among the groups not exposed to gentamicin, the ratio of the means (CFU per milligram of protein) for the group exposed to cytochalasin D compared to the group not exposed to cytochalasin D was 0.969 (95% confidence interval, 0.624 to 1.50). Because the confidence interval for the ratio of the means overlaps 1, the presence of cytochalasin D resulted in no statistically significant difference between infected organ culture samples in the absence of gentamicin. In other words, cytochalasin D did not affect gonococcal viability or gonococcal tissue association. Because this result was consistent through three experiments, these two groups were pooled for data analysis.
The ratio of the gentamicin-treated group exposed to cytochalasin D to the gentamicin-treated group not exposed to cytochalasin D was 0.327 (90% confidence interval, 0.116 to 0.921). Thus, the group treated without cytochalasin D had a greater degree of protection from gentamicin (a poorly penetrating antibiotic), suggesting that more bacteria were intracellular during the time of exposure to the drug. We conclude that cytochalasin D inhibits gonococcal invasion of an FTOC much as it does that of immortalized cell lines.
Ciprofloxacin-versus-cefixime assays. This experiment compared ciprofloxacin and cefixime for intracellular killing effectiveness. Data from a representative experiment are shown in Table 2 . Pooled data from groups not exposed to either antibiotic showed an average of 2.46 ϫ 10 7 CFU/mg of protein. This average represents all tissue-associated gonococci (extraand intracellular).
The ratio of the ciprofloxacin-treated group exposed to cytochalasin D to the group not exposed to cytochalasin D was 0.611 (95% confidence interval, 0.247 to 1.51). Because the confidence interval for their ratios overlaps 1.0, there is no statistically significant difference between the two groups. In two other experiments, the ratios were 1.37 (95% confidence interval, 1.07 to 1.77) and 1.28 (95% confidence interval, 0.773 to 2.11). Thus, ciprofloxacin appeared to kill intracellular gonococci at least as well as extracellular gonococci. The ratio of the cefixime-treated group exposed to cytochalasin D to the group without cytochalasin D exposure was 0.174 (95% confidence interval, 0.0781 to 0.387). Thus, at least 61.3% more of the tissue-associated gonococci were protected from cefixime in the absence of cytochalasin D. This suggests that cefixime did not penetrate epithelial cells well and thus, intracellular gonococci were protected or spared the bactericidal effects of cefixime. In fact, in three replicate experiments in which ciprofloxacin and cefixime were compared, the cytochalasin D/no cytochalasin D ratios for ciprofloxacin were 2.1, 2.28, and 3.5 times as high as the comparable cefixime ratios. This indicates that cytochalasin D consistently had a greater effect on the ability of cefixime to kill gonococci than on that of ciprofloxacin.
When the killing efficacy of ciprofloxacin was compared directly to that of cefixime, the ratio of the group exposed to cytochalasin D and treated with ciprofloxacin to the cytochalasin D-exposed cefixime group was 0.588 (95% confidence interval, 0.267 to 1.30). Thus, there is no statistically significant difference between groups exposed to cytochalasin D and treated with ciprofloxacin or cefixime. This suggests that there is no statistically significant difference in efficacy between the two antibiotics against extracellular attached gonococci, i.e., when invasion has been inhibited by cytochalasin D. However, among groups not exposed to cytochalasin D, the ratio of the ciprofloxacin-treated group compared to the cefixime group was 0.167 (95% confidence interval, 0.0670 to 0.418), indicating that ciprofloxacin killed at least 59.2% more total tissueassociated gonococci than did cefixime. In replicate experiments, the ratio reached a low of 0.0574 (95% confidence interval, 0.0333 to 0.0990) and a high of 0.425 (95% confidence interval, 0.332 to 0.543). Because the confidence intervals do not overlap 1, ciprofloxacin was clearly more effective than cefixime. Given that ciprofloxacin and cefixime were not markedly different in extracellular killing (groups exposed to cytochalasin D), these last differences can be attributed primarily to ciprofloxacin's consistently superior intracellular efficacy.
DISCUSSION
N. gonorrhoeae invades epithelial cells and is believed thereby to resist gentamicin, which penetrates cells poorly (9, 33) . This hypothesis was supported by our findings in the human FTOC model. Gonococci escaped the bactericidal effects of gentamicin despite a gentamicin concentration in the culture that far exceeded safe therapeutic concentrations in serum. An approximately threefold decrease in protection with the use of 12-g/ml cytochalasin D was seen in this gentamicin assay. Other studies done with immortalized cell lines have shown a more dramatic difference between gentamicin-exposed groups with or without cytochalasin D (9, 33) . Perhaps the gonococcal strains used in those other studies were more invasive than our test strain. However, those other studies did not report statistical analyses or indicate the amount of variability between samples, so the viability of this explanation is unclear. It is also interesting that in previous studies using HecIB cells, 20-to 50-g/ml gentamicin was used for a 90-min exposure. These concentrations were ineffective in significantly reducing gonococcal numbers in the human FTOC model. The human fallopian tube mucosa may be able to protect gonococci better than cell line cultures from antibiotics. Perhaps this is due to the high degree of convolution along the epithelial mucosa and the consequent increase in surface area present to protect or shelter attached gonococci. In addition, the number of target cells in our assay may differ from previous work with cell culture models because we cannot directly determine the number of epithelial cells in a punch biopsy. This also explains interexperimental variability in the FTOC system. Although the ratio relationships remained fairly constant across experiments, the absolute numbers of organisms recovered per milligram of protein in experiments using different tissue sources were variable. Different degrees of convolution between patient sources could markedly change the number of epithelial cells harvested from one patient to the next. The amount of adventitial tissue remaining in each punch biopsy would also be expected to vary from experiment to experiment, giving a different denominator in each case. Besides making comparisons to other models difficult, these are also the reasons for not making cross-experiment data comparisons and for not pooling data from different experiments which we performed.
Note also that processing of each tissue sample took approximately 5 to 8 min from homogenizing of the sample and sterilizing of the Tissumizer homogenization probe. As a result, processing of all tissues after exposure to the antibiotic caused a time delay of 2.5 to 4.0 h between the first tissue homogenate and the last, depending on the number of samples processed. The processing time for samples was noted to assess whether processing delays affected organism recovery over time. No significant increase in organism recovery over time was noted in any of the experiments, despite antibiotic removal. This indicates that the time of exposure and concentrations of gentamicin, ciprofloxacin, and cefixime prevented measurable growth of gonococci for up to 4 h postexposure. This suggests that gonococci do not replicate inside fallopian tube epithelial cells, but the possibility cannot be excluded that sublethal exposure to antibiotics coupled with a suboptimal intracellular growth environment inhibited a normal low level of replication.
In this human fallopian tube model, ciprofloxacin achieved better gonococcal killing than cefixime. This difference in efficacy was due to greater intracellular killing by ciprofloxacin. The superiority of ciprofloxacin occurred even though the ratio of the drug concentration to the MIC was greater for cefixime than for ciprofloxacin in the culture medium. This difference in efficacy in vitro has two plausible explanations. First, ciprofloxacin penetrated epithelial cells better than cefixime did, resulting in greater exposure of gonococci to the drug. Indeed, fluoroquinolones have been shown to penetrate macrophages, fibroblasts, and neutrophils extremely well, achieving intracellular levels two-to eightfold higher than extracellular concentrations (2, 19) . In contrast, cefotaxime, an expanded-spectrum cephalosporin similar to cefixime, has been shown to penetrate neutrophils poorly, with an intracellular-to-extracellular ratio of 0.3 (24) . Alternatively, intracellular gonococci may simply be more sensitive to ciprofloxacin than cefixime due to their different mechanisms of action. Ciprofloxacin is bactericidal to susceptible gram-negative organisms immediately upon exposure even if they are not actively growing (40) . In contrast, the bactericidal effect of cefixime, like that of all ␤-lactam antibiotics, is slower because it is dependent on active cell wall synthesis. It is possible that despite intracellular penetration by cefixime, the gonococci were not in a logarithmic growth phase and, thus, were relatively less susceptible to cefixime. In fact, the effects of cytochalasin D were more easily demonstrated for cefixime in the FTOC model than for the standard antibiotic for this type of assay, gentamicin. This difference might be related to our difficulty in optimizing the gentamicin concentration for the FTOC model rather than any real difference in the intracellular penetration of the two antibiotics. Nevertheless, this sparing of intracellular gonococci by cefixime could be put to good use in studying the pathogenesis of gonococcal invasion by using different gonococcal variants in the FTOC model. Ciprofloxacin or cefixime is suitable for the treatment of uncomplicated gonorrhea. Neither of these drugs is currently recommended for oral therapy of acute salpingitis, and we have not attempted to simulate the pharmacodynamics of a treatment course for acute salpingitis. Nevertheless, the results have significance for the treatment of gonococcal infections, because they illustrate the behavior and properties of these drugs in a natural target tissue of these infections, the human fallopian tube. These data are also relevant to infection of endocervical columnar epithelial cells, for which single-dose oral ciprofloxacin or cefixime is commonly prescribed.
Hypothetically, cefixime treatment failures might occur as MICs slowly increase before the MICs for the organisms reach the susceptibility breakpoint. This might happen if the higher MIC allows intracellular bacteria to escape the relatively lower intracellular antibiotic concentration effects. Recently, a study compared single-dose cefuroxime to ciprofloxacin for the treatment of uncomplicated gonorrhea (36) . That study showed that cefuroxime had more therapeutic failures (difference, Ϫ7%; 95% confidence interval, Ϫ11 to Ϫ3%) than ciprofloxacin in male urethritis despite susceptibility of the clinical isolates to each antibiotic in vitro. In the group that failed, MICs of cefuroxime tended to be higher than in the group that was successfully treated with cefuroxime, although this trend did not reach statistical significance. Cefuroxime has been shown to penetrate human umbilical vein endothelial cells poorly (10) , like other ␤-lactam antibiotics. This lends support to the potential importance of "MIC creep" for facultative intracellular pathogens that are treated with antibiotics that have poor intracellular penetration. One could hypothesize that ciprofloxacin would tolerate rising MICs for gonococci better than cefixime before treatment failures start to occur because of ciprofloxacin's intracellular advantage. However, before concluding that ciprofloxacin is a better choice than cefixime for the treatment of gonorrhea, one must consider the worldwide MIC trends for these antibiotics. Treatment failures for gonococcal isolates for which the ciprofloxacin MIC is 1.0 g/ml and the ofloxacin MIC is 2.0 g/ml have been reported in Australia, the United Kingdom, Hong Kong, the Republic of the Philippines, and the United States (3, 6, 14, 17, 18, 35) . In 1994, the Gonococcal Isolates Surveillance Project sponsored by the Centers for Disease Control and Prevention found that only 0.04% (2 of 5,000) of the clinical isolates in the United States were resistant to ciprofloxacin (MIC, 1.0 g/ml). However, intermediate resistance (MIC, 0.125 to 0.5 g/ml) has been on the rise, increasing steadily from 0.3% (17 of 5,238) in 1991 to 1.3% (65 of 5,000) in 1994 (8a). Currently, ciprofloxacin resistance is unusual in the United States, but a sustained outbreak of quinolone-resistant gonococci has been reported (6) . In contrast to the increasing resistance to fluoroquinolones, there have been no reports of rising gonococcal resistance to ceftriaxone or cefixime in the United States (8a). If quinolone resistance becomes more widespread than it is currently, the intracellular killing advantage of ciprofloxacin could be negated. Sparing of extracellular organisms for which the MIC has exceeded the susceptibility breakpoint would be expected to result in treatment failure.
In conclusion, protection of gonococci from gentamicin is microfilament dependent in the human FTOC model, as it is inhibited by cytochalasin D, which prevents gonococcal invasion. This is also true for cefixime. However, an intracellular location does not protect gonococci from ciprofloxacin. This difference can be ascribed to the known superior intracellular penetration of ciprofloxacin. Intracellular bacterial sparing by cefixime or gentamicin might be applied to study gonococcal invasion in future FTOC experiments. Lastly, enthusiasm for the superior killing of the facultative intracellular pathogen N. gonorrhoeae by ciprofloxacin treatment in our model needs to be tempered if quinolone resistance in clinical isolates becomes more prevalent.
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